LIFR and prostate carcinoma: Among the cytokines increased in ADT patients were leukemia inhibitory factor receptor (LIFR, a receptor for the IL-6-like cytokine LIF), IL-1 receptor antagonist, IL-10, chemokine ligand (CCL)2, a chemokine known to contribute to prostate cancer resistance, and the IL-17RA receptor [172,173].